Market Scenario
The Global Healthcare Contract Manufacturing Market 2020, according to the MRFR analysis, is poised to mature at a 9.86% CAGR and is projected to reach USD 250.9 Billion by 2023.
Market Dynamics
The expiration of patents for major drugs and medical devices, competition and production and trade economics to favor contract manufacturing organization (CMO), mutual benefit to contract manufacturer and customer, and lean manufacturing and agility are some of the major drivers for the growth of contract manufacturing market for healthcare across the globe. A big patent cliff is occurring worldwide, especially in the pharmaceutical industry, in the healthcare sector. The patent cliff will lead to cheaper generic versions on the market , increasing demand for CMOs. Thus, the expiration of patent protection for major prescription drugs and the increasing demand for generic drugs are likely to enhance the growth of CMOs globally. In the other hand, the uncertainty of the supply chain and third party management problems and standardization and interoperability concerns are anticipated to impede business growth over the projected period.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5637
Segmentation
The global market for healthcare contract manufacturing has been analyzed on the basis of service type, type, and lastly, industry.
The type-based segmentation of the global CMO market comprises of sterile and non-sterile.
The service-based segmentation of the global CMO market comprises pharmaceutical industry, medical device industry, and biopharmaceutical industry.
The industry-based segmentation of the global CMO market comprises medical device industry, pharmaceutical industry, and biopharmaceutical industry. Due to the rampant growth of the global medical device industry, the segment of medical devices led the market in 2016 by holding 43.7 per cent market revenue share.
Regional Summary
The global healthcare contract manufacturing market, based on region, is segmented into the Americas, Europe , Asia-Pacific, and Middle East & Africa.
Driven by the presence of major pharmaceutical drug manufacturers, thriving pharmaceutical industry and leading medical device companies in the US and Canada, the Americas currently dominates the global healthcare contract manufacturing market.
Generic drug companies are the main customer base of contract manufacturers in Europe, contributing to the growth of the European CMO market. Important factors influencing European market growth include the presence of major manufacturers, Increase in the biopharmaceutical sector , government support for R&D, increased disposable income and the availability of technologically advanced products.
Asia-Pacific should record a comparatively higher CAGR over the forecast period. Countries like China and India continue to draw significant amounts of outsourcing work from developed countries due to factors such as large-scale production capacity , low labor costs , low cost of raw materials and low cost of manufacturing. Besides that, some of the key factors driving demand growth include rising healthcare spending, increasing manufacturers' R&D funding, and moreover multinational medical device manufacturers seeking opportunities in the region and expanding their presence in the region. The changing regulatory landscape of medical devices has been a concern for the region's contract-manufacturing healthcare market.
The Middle East & Africa contributes least to the global contract manufacturing market in the healthcare sector. The growing development of the medical sector in the Middle Eastern countries, increased R&D spending and the expansion of multinational companies in the region also influence market growth.
Competitive Dynamics
The eminent players in the global healthcare contract manufacturing market are Lonza AG, Boehringer Ingelheim, Grifols International, S.A, Catalant, Aesica Pharmaceuticals, AbbVie, Benchmark Electronics, Evonik Industries, Flex Ltd, Teva Pharmaceutical Industries, Forefront Medical Technologies, Hamilton Company, Sanmina Corporation, Mylan, Patheon, and Vetter Pharma International.
Industry Update
August 2020 - BioStem Technologies, Inc., a leading life sciences company specializing in the development and sale of perinatal tissue-based allografts for use in regenerative therapies, announced that its subsidiary, Blue Tech Industries, Inc. signed a Master Service Agreement with a new customer to manufacture the customer’s amniotic membrane platform for the next two years, in a deal estimated to be worth up to USD 2.4 million to BioStem.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/healthcare-contract-manufacturing-market-5637
About Market Research Future:
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.j
Contact
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: [email protected]
The global Gastroesophageal Reflux Disease (GERD) therapeutics market size was valued at USD 5.66 billion in 2016 and by is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%.
Expiration of patented blockbuster drugs, which are indicated for the management of disorders of acid reflux is major restraining factors for this market.
Rising number of companies being exposed to price scrutiny associated with shift in the focus of government on the promotion of consumer convenience will stimulate further reduction of drug prices.
Although market turnover is affected by the expiration of major patents and the demand of drugs used to reduce acid, due to the increasing prevalence of heartburn, is anticipated to increase in the upcoming years.
Hence, very limited acceptance of devices of GERD management contribute for the rising demand of drugs having acid neutralizing property, as the major therapy approach.
Nevertheless, the advent of devices which are minimally invasive to address anatomical defects are gaining popularity coupled with supportive evidence from clinical data for performing various procedures including trans oral fundoplication, which helps in preventing reflux of non-acid and acid contents.
